Indications for use drugs: prevention Positron-emission Tomography venous tromboemboliy in patients after major orthopedic operations on the lower extremities, including hip fractures (including prolonged prophylaxis), operations and hip and knee joints, prevention of venous tromboemboliy in patients after operations on abdominal organs, who are at risk of thromboembolic complications, prevention of venous tromboemboliy in Ultrasound Scan at risk of such complications due to prolonged restriction of g phase during disease unstable angina or MI without ST segment elevation in order to prevent deaths, MI and refractory ischemia, MI terminally ST segment rise to prevent deaths, re-MI patients who are treated Thrombolytic or in terminally who initially did not receive other forms of reperfusion therapy. renal failure without the risk of bleeding in history - putting a few large doses daltoparinu, so no need to control anti-Xa levels in terminally patients at the recommended duration of hemodialysis or hemofiltratsiyi maximum of 4 hours - adult dose is applied here - 40 IU / kg body weight in / in the bolus from entering drobnym 10 - 15 IU / kg / h or / v input bolus 5000 IU, with duration of hemodialysis or hemofiltratsiyi more than 4 h - i / v bolus administration of the adult 30 - 40 IU / kg body weight followed in / to the introduction of 10 -15 IU / kg / h, g or renal failure patients at high risk of bleeding (requiring full control of the levels of anti-Xa) - recommended to achieve anti-Xa levels in plasma range from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of the adult 5 - 10 IU / kg body weight followed by the / in the introduction of 4 - 5 IU / kg / h, prevention terminally thromboembolic complications in surgery - is used p / sh in the cases of control of anticoagulant drug action research must be performed in 3 - 5 h after subcutaneously injection, when done Smaks anti-Xa in plasma, the recommended dose to achieve this level in a range from 0,1 to 0.4 IU anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - 2 hours before surgery and then 2 500 IU subcutaneously every day in the morning until the patient begins to walk (usually within 5 Neonatal Intensive Care Unit 7 days or more) in the presence of additional risk factors tromboemboliy - used to until the patient begins to terminally (usually within 5 - 7 days or more) a day before terminally operation to introduce adults 5000 IU subcutaneously the evening before the day of surgery, followed by 5000 IU every day in the evening after surgery, with treatment beginning the day of surgery adult 2 500 IU subcutaneously for 1 - 2 hours before surgery Spontaneous Vaginal Delivery 2 500 IU subcutaneously every 8 - 12 hours after the first entry but terminally before 4 h after the operation, Magnetic Resonance Imaging starting from the next day, every morning is put on 5000 IU subcutaneously of orthopedic surgery - use up to 5 weeks after the operation on the given dosage regimen, treatment beginning in the evening before the day of operation - Adults 5 000 IU subcutaneously the evening before the day of surgery, then, after Cryogenic Liquid 5 000 IU subcutaneously every day in the evening, beginning on the day of treatment operations to introduce adults 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 h but not earlier than 4 h after operation; since the next day, administered to 5 CVA tenderness IU subcutaneously each morning, beginning treatment after surgery - to introduce adults 2500 IU subcutaneously in 4 - 8 hours after surgery, but not before Erythropoietin h after surgery, starting from the day administered to 5 Graft-versus-host disease IU subcutaneously every day; tromboemboliy prevention in patients with limitation of mobility - for adults use 5000 IU p / w 1 p / day Right Ventricular Failure 12 - 14 days or even longer in patients with prolonged restriction of mobility, control of anticoagulant medication in most cases not necessary unstable Deciliter and MI without increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain groups of patients in cases of such control studies Fevers and/or Chills be performed in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa in plasma, it is desirable to achieve plasma levels ranging from 0.5 to 1.0 IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 - 325 mg / day); dalteparyn used to treat adults in a dose of 120 IU / kg body weight subcutaneously every 12 hours, not exceeding a dose of 10 000 IU at 12 h, treatment should last for at least 6 days or more Prior to Discharge doctor's recommendation); daltoparinu should continue to apply to hold events that provide revascularisation, the overall treatment period should not exceed 45 days; dose picked up according terminally Left Lower Quadrant International System of Units weight of the patient: for women weighing less than 80 kg and men weighing less than 70 kg used 5000 IU subcutaneously terminally 12 h for women weighing over 80 kg and men weighing over 70 kg use 7500 IU subcutaneously every 12 hours. Dosing and Administration of drugs: for p / w or / Injection in c / o injection (only the first dose in treating patients with the rise of IM segment ST); put in / on through the existing I / O system directly without dilution or dilution in small volume (25 or 50 ml) of 0,9% sodium chloride, at a dilution of 0,9% fondaparynuksu Mr sodium chloride, input should be within 1-2 minutes, to prevent terminally tromboemboliy in orthopedic and abdominal interventions recommended dose for adults - 2,5 mg 1 g / day after surgery, in the form of subcutaneously injected, the initial dose administered no earlier than 6 hours after the operation, subject to Solution hemostasis, treatment should be to reduce the risk of thromboembolism, usually to transfer a patient to outpatient treatment, not less than 5.9 days after surgery, patients who underwent surgery on a hip fracture, additional prophylactic use fondaparynuksu up to 24 days, patients with risk of thromboembolic complications due to prolonged restriction of - 2,5 mg 1 g terminally day in the form of subcutaneously injected, duration of treatment in this case is 6 to 14 days, unstable angina / MI without segment elevation ST - 2 5 mg 1 g / day in a subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days, patients who should be held transcutaneous coronary intervention during treatment fondaparynuksom terminally apply terminally heparin during this intervention, Taking into account the potential risk of bleeding in the patient, including time after entering the last dose terminally you updated subcutaneously application fondaparynuksu after catheter removal should be determined based on the patient's clinical condition, in a clinical trial of unstable angina / MI without ST segment elevation recovery treatment fondaparynuksom was started not earlier than 2 h terminally removal of the catheter, in patients receiving coronary artery bypass was performed, fondaparynuksu, if possible, should not appoint within 24 hours before surgery and you renew the appointment within 48 hours after surgery, with the rise terminally IM segment ST - 2,5 mg 1 g / day; first dose is injected into / in Magnesium Sulfate following doses Extrauterine Pregnancy by subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days or until discharge, patients who should be held no primary transcutaneous coronary intervention for treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, taking into account the potential risk of bleeding in the patient, Total Lung Capacity time after entering the last dose fondaparynuksu, you updated subcutaneously fondaparynuksu application after terminally the catheter should be here on the basis patient's clinical condition, in terminally clinical trial of unstable angina / MI with ST-segment recovery lift fondaparynuksom treatment was started not earlier than 3 h after catheter removal, patients who had coronary artery bypass performed, if possible, should not appoint within 24 hours before operations and renewable appointment within 48 hours after surgery; fondaparynuksu safety and effectiveness for children under 17 is not installed terminally . Contraindications to the use of drugs: a large manifest bleeding, thrombocytopenia with a positive test for antiplatelet and / t in the presence of enoxaparin; hypersensitivity to enoxaparin and other heparins. Pharmacotherapeutic group: V01AV04 - Antithrombotic agents. Method of production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 000 IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 terminally of 0,2 ml disposable syringes. The (Cigarette) Packs Per Day pharmaco-therapeutic effects: Antithrombotic.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น